CJC-1295 / Ipamorelin Blend: Research, Mechanism & Scientific Overview

What Is the CJC-1295 / Ipamorelin Blend?

The CJC-1295 (No DAC) + Ipamorelin blend is a pre-formulated research peptide that combines two distinct compounds at the top of the growth hormone axis. CJC-1295 (without the Drug Affinity Complex, commonly abbreviated "No DAC") is a synthetic, modified analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a pentapeptide growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a).

Although each peptide can stimulate pituitary GH release on its own, they act on entirely different receptor systems. When administered together, research has documented a synergistic increase in growth hormone output that exceeds the sum of either compound administered alone, while preserving the pulsatile nature of endogenous GH secretion. For this reason, the combination has become one of the most studied GHRH/GHRP stacks in preclinical research.

Blend Profile

Blend Composition

Components: CJC-1295 (No DAC) + Ipamorelin
Ratio: 5 mg / 5 mg (equal parts)
Total Per Vial: 10 mg
CJC-1295 Class: Modified GHRH analog (29 aa)
Ipamorelin Class: Selective GH secretagogue (5 aa)

Mechanism of Action

The rationale for combining CJC-1295 and Ipamorelin lies in their complementary mechanisms. GH secretion is normally driven by two hypothalamic inputs, GHRH (which activates the GHRH receptor on pituitary somatotrophs) and ghrelin (which activates the GHS receptor). The blend activates both pathways simultaneously.

CJC-1295 (No DAC), GHRH Receptor Activation

CJC-1295 is a 29-amino-acid modified GHRH(1-29) analog. It incorporates four amino acid substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27) that confer resistance to enzymatic degradation by DPP-IV and other peptidases. Unlike CJC-1295 with DAC (which binds albumin for week-long half-life), CJC-1295 No DAC maintains a shorter, more physiologically timed half-life of approximately 30 minutes. This shorter action preserves the body's natural pulsatile GH release pattern.

Ipamorelin, Ghrelin Receptor Activation

Ipamorelin is a 5-amino-acid synthetic peptide that selectively activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. Unlike first-generation GHRPs such as GHRP-2 or GHRP-6, Ipamorelin has been characterized in research as highly selective for GH release, without the substantial cortisol, ACTH, aldosterone, or prolactin elevations associated with earlier compounds.

The Synergy Mechanism

When GHRH and GHRP pathways are activated simultaneously, the pituitary somatotrophs respond with greater GH output than either stimulus produces alone. Research has attributed this synergy to several complementary effects: (1) GHRH primes somatotrophs by increasing cAMP, (2) GHRPs (via ghrelin receptor) amplify GH release by antagonizing somatostatin tone and releasing additional GH reserves, and (3) the two pathways reinforce each other at the downstream level of vesicle exocytosis.

Preservation of Pulsatility

A distinctive feature of the CJC-1295 (No DAC) + Ipamorelin combination is that, because both compounds have relatively short half-lives, they produce discrete GH pulses rather than a sustained elevation. This has been described in the research literature as more closely mimicking physiological GH secretion than long-acting alternatives, which produce prolonged non-pulsatile elevation.

Research Overview

GHRH/GHRP combination research has a substantial history in endocrinology, with both peptides individually and in combination having been characterized over decades.

Research Area	Key Findings	Study Type
GH Release Synergy	Combined GHRH analog + GHRP administration has been consistently shown to produce supra-additive GH release relative to either alone	Human clinical / in vivo
Ipamorelin Selectivity	Studies established Ipamorelin as a GH secretagogue with minimal off-target elevation of cortisol, ACTH, or prolactin	Human clinical
Pulsatile GH Secretion	Short-acting GHRH analogs combined with GHRPs have been shown to preserve the natural pulsatile GH secretion pattern	In vivo (rodent, human)
IGF-1 Elevation	GHRH/GHRP combination research has documented downstream IGF-1 elevation reflecting sustained, pulsatile GH stimulation	Human clinical
Body Composition (preclinical)	Animal studies have investigated effects on lean mass, fat mass, and metabolic parameters	In vivo (rodent)
Recovery Research	Preclinical models have examined GH-axis activation in recovery from exercise-induced muscle stress	In vivo (rodent)

Research Context

The individual components of this blend, Ipamorelin and modified GHRH analogs, have robust preclinical and some human clinical research backgrounds. The specific fixed-ratio pre-blended formulation is primarily used in research and is sold strictly for laboratory purposes. Findings from preclinical and short-term clinical studies do not necessarily translate to long-term human outcomes.

Common Areas of Research Interest

The GHRH + GHRP combination model is used in multiple research domains focused on growth hormone physiology.

Growth hormone axis pharmacology, Fundamental research on GH pulse dynamics, somatotroph function, and feedback regulation
IGF-1 signaling, Studies examining how pulsatile GH stimulation translates into downstream IGF-1 elevation
Body composition research, Preclinical investigation of GH-axis effects on lean mass, adiposity, and metabolism
Recovery and tissue repair, Animal models examining GH-axis activation in exercise recovery and injury response
Somatopause and aging, Research on age-related GH decline and strategies to restore youthful GH pulsatility
Ghrelin receptor biology, Investigation of GHS-R1a signaling and its integration with the GH axis

Pharmacokinetics

Both components in this blend have relatively short half-lives, which is a defining feature of this particular stack and distinguishes it from long-acting alternatives such as CJC-1295 with DAC.

~30 min

CJC-1295 No DAC Half-Life

~2 h

Ipamorelin Half-Life

GHRH-R + GHS-R

Dual Receptor Activation

Pulsatile

GH Release Pattern

The combined half-life profile of this blend produces a relatively short, discrete window of GH stimulation, typically several hours, after which GH secretion returns to baseline. This is in direct contrast to long-acting analogs such as CJC-1295 + DAC, which produce sustained GH elevation over a week or more. The short-acting, pulsatile profile of the No DAC + Ipamorelin combination has been a key reason for its prevalence in research contexts focused on preserving physiological GH rhythm.

Comparison to Similar Peptides and Blends

The CJC-1295 (No DAC) + Ipamorelin blend sits in a specific niche within the broader category of GH-releasing peptides and can be contrasted with related research compounds.

Feature	CJC-1295 No DAC + Ipamorelin	CJC-1295 + DAC	Tesamorelin (alone)
Mechanism	Dual: GHRH + ghrelin receptors	Single: GHRH receptor	Single: GHRH receptor
Half-Life	Short (minutes to hours)	Long (~1 week)	Short (~26 min)
GH Release Pattern	Pulsatile	Sustained elevation	Pulsatile
Research Synergy	Dual-pathway amplification	Single-pathway, extended	Single-pathway, acute

Frequently Asked Questions

Why combine CJC-1295 and Ipamorelin instead of using one alone?

The two peptides act on different receptors: CJC-1295 on the GHRH receptor, Ipamorelin on the ghrelin receptor. Research has consistently shown that combined activation produces substantially greater GH release than either pathway alone, and the synergy is a central reason this stack has been widely studied.

What is the difference between CJC-1295 With DAC and No DAC?

"DAC" stands for Drug Affinity Complex, a modification that binds the peptide to serum albumin, extending the half-life to roughly 1 week. Without DAC, CJC-1295's half-life is approximately 30 minutes. The No DAC version produces pulsatile GH release; the With DAC version produces sustained GH elevation.

Why is Ipamorelin considered "selective"?

Older GH-releasing peptides such as GHRP-6 and GHRP-2 stimulate GH release but also raise cortisol, ACTH, aldosterone, or prolactin. Ipamorelin has been characterized in research as producing GH release with minimal off-target hormonal elevation, earning the "selective GH secretagogue" designation.

Does the blend produce more GH than either alone?

Yes, consistently in the research literature. GHRH/GHRP combination studies have shown supra-additive GH release relative to either compound individually, a synergistic effect that is the basis for the popularity of this stack in preclinical and clinical research.

What is the 50/50 ratio and why?

This blend contains 5 mg of CJC-1295 No DAC and 5 mg of Ipamorelin, the most common research ratio. Equal dosing reflects the typical dosing conventions in the published literature for GHRH/GHRP synergy studies.

Is this blend suitable for long-term GH research?

Because both components have short half-lives, the blend is oriented toward studies modeling acute or episodic GH stimulation rather than sustained GH elevation. Long-term research setups may use different GH-axis tools depending on the specific question.

Sources & References

Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. PubMed
Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PubMed
Bowers CY, et al. "Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women." Journal of Clinical Endocrinology & Metabolism. 2004;89(5):2290-2300. PubMed
Sinha DK, et al. "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males." Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. PubMed
Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sexual Medicine Reviews. 2018;6(1):45-53. PubMed
Bowers CY, et al. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology. 1984;114(5):1537-1545.

Explore the CJC-1295 / Ipamorelin Blend

Available for research purposes. Third-party tested for purity and identity.

View Blend Products — $80

This product is intended for research and laboratory use only. It is not intended for human consumption.

Disclaimer: This content is provided for educational and informational purposes only. It is not intended as medical advice, nor does it constitute a recommendation for the treatment, cure, or prevention of any disease or condition. This blend is sold for research purposes only and is not intended for human consumption. Always consult a qualified healthcare professional before making decisions about your health. Somata Peptides does not claim that any products treat, cure, or prevent any disease.

CJC-1295 + Ipamorelin: Dual-Pathway GH Blend